Anaptysbio (ANAB) Liabilities and Shareholders Equity (2016 - 2026)

Anaptysbio (ANAB) has 11 years of Liabilities and Shareholders Equity data on file, last reported at $329.7 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 21.89% year-over-year to $329.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 billion (down 24.32% YoY) and the FY2025 annual result came in at $364.4 million, down 24.69% from the prior year.
• Liabilities and Shareholders Equity eased to $329.7 million in Q1 2026, from $364.4 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $625.2 million in Q1 2022 to a low of $329.7 million in Q1 2026.
• A 5-year average of $475.4 million and a median of $483.8 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity soared 57.7% — and 2025, when it dropped 28.44%.
• Tracing ANAB's Liabilities and Shareholders Equity over 5 years: stood at $610.4 million in 2022, then fell by 25.88% to $452.4 million in 2023, then grew by 6.95% to $483.8 million in 2024, then retreated by 24.69% to $364.4 million in 2025, then retreated by 9.53% to $329.7 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $329.7 million (Q1 2026), $364.4 million (Q4 2025), and $353.1 million (Q3 2025), per Business Quant data.